CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


SMS message supportWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug551 Chat-based instant messaging support Wiki 1.00
drug2216 Self-help booklet Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D012008 Recurrence NIH 1.00

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Chat-based Instant Messaging Support for Preventing Smoking Relapse in the Context of COVID-19 Outbreak: a Pilot Randomised Clinical Trial

This pilot trial aims to evaluate the effectiveness of chat-based instant messaging support in preventing smoking relapse in recent tobacco abstainers.

NCT04409496 Smoking Cessation Behavioral: Chat-based instant messaging support Behavioral: SMS message support Behavioral: Self-help booklet
MeSH:Recurrence

Primary Outcomes

Description: Defined by an exhaled carbon monoxide level of 3 parts per million or below

Measure: Biochemically-validated tobacco abstinence

Time: Assessed at 6 months after randomisation

Secondary Outcomes

Description: Not more than five lapses permitted for 6 months after baseline

Measure: Self-reported 6-month prolonged tobacco abstinence

Time: Assessed at 6 months after randomisation

Description: Being completely smoke-free in the past 7 days

Measure: Self-reported 7-day point-prevalence tobacco abstinence

Time: Assessed at 3 months after randomisation

Description: Being completely smoke-free in the past 7 days

Measure: Self-reported 7-day point-prevalence tobacco abstinence

Time: Assessed at 6 months after randomisation

Description: Defined as use of tobacco products for 7 consecutive days or longer

Measure: Self-reported relapse rate

Time: Assessed at 3 months after randomisation

Description: Defined as use of tobacco products for 7 consecutive days or longer

Measure: Self-reported relapse rate

Time: Assessed at 6 months after randomisation

Other Outcomes

Description: Assessed by the Chinese version of the Smoking Self-efficacy Questionnaire (SEQ-12), which contains 12 Likert items ranging from 1 (not certain at all) to 5 (very certain) with higher scores indicating greater perceived confidence in resisting smoking.

Measure: Change in self-efficacy to quit smoking

Time: Assessed at 3 months after randomisation

Description: Assessed by the Chinese version of the Smoking Self-efficacy Questionnaire (SEQ-12), which contains 12 Likert items ranging from 1 (not certain at all) to 5 (very certain) with higher scores indicating greater perceived confidence in resisting smoking.

Measure: Change in self-efficacy to quit smoking

Time: Assessed at 6 months after randomisation

Description: Assessed by the Chinese verion of the Minnesota Nicotine Withdrawal Scale (MNWS), which contains 9 Likert items ranging from 0 (not at all) to 4 (very severe) with higher scores indicating greater nicotine withdrawal.

Measure: Nicotine withdrawal

Time: Assessed at 3 months after randomisation

Description: Assessed by the Chinese verion of the Minnesota Nicotine Withdrawal Scale (MNWS), which contains 9 Likert items ranging from 0 (not at all) to 4 (very severe) with higher scores indicating greater nicotine withdrawal.

Measure: Nicotine withdrawal

Time: Assessed at 6 months after randomisation


No related HPO nodes (Using clinical trials)